HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $54 price target.
June 17, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $54 price target.
The reiteration of a Buy rating and the maintenance of a $54 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100